Jakafi™ is the trade for the generic chemotherapy drug ruxolitinib. In some cases, health care professionals may use the generic drug name ruxolitinib when
referring to the trade name Jakafi™.
Jakafi™ is a targeted therapy. It is an oral receptor tyrosine kinase inhibitor - (For more detail, see "How this drug works," below.)
What this drug is used for:
For the treatment of intermediate and high risk myelofibrosis.
Note: If a drug has been approved for one use, physicians may elect to use this same drug for other problems if they believe it may be helpful.
How this drug is given:
Jakafi™ is a pill, taken by mouth, with or without food.
Take Jakafi™ exactly as prescribed, even if you are feeling better.
Swallow Jakafi™ tablets whole. Do not chew, crush or break.
Those who have feeding tubes may also use the tablet. Mix each tablet with 40 mL of water. Stir for 10 minutes. Give within 6 hours of mixing. Flush
the feeding tube with water before and after this drug is given.
Do not change your dose or stop Jakafi™ unless your health care provider tells you to.
If a dose is missed, return to the usual dosing schedule. Do not take an additional dose.
Do not take extra doses of Jakafi™. Call your health care provider right away if you take too much.
Avoid grapefruit, grapefruit juice, and supplements that contain grapefruit extract while taking Jakafi™. Grapefruit products may increase the amount
The amount of Jakafi™ that you will receive depends on many factors, your general health or other health problems, and the type of cancer or condition
Important things to remember about the side effects of Jakafi™:
Most people do not experience all of the side effects listed.
Side effects are often predictable in terms of their onset and duration.
There are many options to help minimize or prevent side effects.
There is no relationship between the presence or severity of side effects and the effectiveness of the medication.
The following side effects are common (occurring in greater than 30%) for patients taking
These side effects are less common side effects (occurring in about 10-29%) of patients receiving
Not all side effects are listed above. Some that are rare (occurring in less than 10% of patients) are not listed here. However, you should always
inform your health care provider if you experience any unusual symptoms.
When to contact your doctor or health care provider:
Contact your health care provider immediately, day or night, if you should experience any of the following symptoms:
Fever of 100.4° F (38°C or higher, chills)
- Signs of a very bad reaction (wheezing, chest tightness, fever, itching, bad cough, blue or grey skin color, seizures, or swelling or the face, lips,
tongue or throat)
Always inform your health care provider if you experience any unusual symptoms.
The following symptoms require medical attention, but are not an emergency. Contact your health care provider within 24 hours of noticing any
of the following:
Diarrhea (4-6 episodes in a 24-hour period)
Nausea (interferes with ability to eat and unrelieved with prescribed medication)
Vomiting (vomiting more than 4-5 times in a 24 hour period)
Unable to eat or drink for 24 hours or have signs of dehydration: tiredness, thirst, dry mouth, dark and decrease amount of urine, or dizziness
Skin or the whites of your eyes turn yellow
Urine turns dark or brown (tea color)
Pain on the right side of your stomach
Bleed or bruise more easily than normal
- Signs of infection (very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound
that will not heal or anal itching or pain)
Headache, back pain or joint pain
- Skin changes (rash, acne, itching, blisters, peeling, redness or swelling)
Always inform your health care provider if you experience any unusual symptoms.
may interact with many types of medications. Before starting Jakafi™ treatment, make sure you tell your doctor about any other medications you are taking (including prescription,
over-the-counter, vitamins, herbal remedies, etc.).
Do not receive any kind of immunization or vaccination without your doctor's approval while taking Jakafi™.
Inform your health care professional if you are pregnant or may be pregnant prior to starting this treatment. Pregnancy category C (use in pregnancy
only when benefit to the mother outweighs risk to the fetus).
For both men and women: Do not conceive a child (get pregnant) while taking Jakafi™. Barrier methods of contraception, such as condoms, are recommended
during treatment. Discuss with your doctor when you may safely become pregnant or conceive a child after therapy.
Do not breast feed while taking this medication.
Drink at least two to three quarts of fluid every 24 hours, unless you are instructed otherwise.
You may be at risk of infection so try to avoid crowds or people with colds, and report fever or any other signs of infection immediately to your
Wash your hands often. Do not touch your eyes or the inside of your nose unless you have just washed your hands and have not touched anything else in
- Ask your doctor or nurse before scheduling dental appointments or procedures.
Use an electric razor to minimize bleeding.
- Avoid contact sports or activities that could cause injury.
If you should experience nausea, take anti-nausea medications as prescribed by your doctor, and eat small frequent meals. Sucking on lozenges and
chewing gum may also help.
Avoid sun exposure. Wear SPF 15 (or higher) sun block and protective clothing.
In general, drinking alcoholic beverages should be kept to a minimum or avoided completely. You should discuss this with your doctor.
Get plenty of rest.
Maintain good nutrition.
If you experience symptoms or side effects, be sure to discuss them with your health care team. They can prescribe medications and/or offer other
suggestions that are effective in managing such problems.
Monitoring and testing:
You will be checked regularly by your health care professional while you are taking Jakafi™. Testing may include blood work that checks blood counts and
How this drug works:
Targeted therapy is the result of about 100 years of research dedicated to understanding the differences between cancer cells and normal cells. To date,
cancer treatment has focused primarily on killing rapidly dividing cells because one feature of cancer cells is that they divide rapidly. Unfortunately,
some of our normal cells divide rapidly too, causing multiple side effects.
Targeted therapy is about identifying other features of cancer cells. Scientists look for specific differences in the cancer cells and the normal cells.
This information is used to create a targeted therapy to attack the cancer cells without damaging the normal cells, thus leading to fewer side effects.
Each type of targeted therapy works a little bit differently but all interfere with the ability of the cancer cell to grow, divide, repair and/or
communicate with other cells.
There are different types of targeted therapies, defined in three broad categories. Some targeted therapies focus on the internal components and function
of the cancer cell. The targeted therapies use small molecules that can get into the cell and disrupt the function of the cells, causing them to die. There
are several types of targeted therapy that focus on the inner parts of the cells. Other targeted therapies target receptors that are on the outside of the
cell. Therapies that target receptors are also known as monoclonal antibodies. Antiangiogenesis inhibitors target the blood vessels that supply oxygen to
the cells, ultimately causing the cells to starve.
Jakafi™ is a targeted therapy that targets and binds to the tyrosine kinase receptors and inhibits Janus Associated Kinases (JAK1 and JAK2) which mediate
the signaling of a number of cytokines and growth factors that are important for hematopoiesis and immune function. By binding to these receptors, Jakafi™
blocks important pathways that promote cell division. Myelofibrosis (MF) is a myeloproliferative neoplasm (MPN) known to be associated with dysregulated
JAK1 and JAK2 signaling. Patients with MF who either carry the JAK2 V617 mutation or does not have the JAK2 V617F mutation may both respond to Jakafi™.
Research continues to identify which cancers may be best treated with targeted therapies and to identify additional targets for more types of cancer.
We strongly encourage you to talk with your health care professional about your specific medical condition and treatments. The information contained in
this website is meant to be helpful and educational, but is not a substitute for medical advice.